Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Mankind Pharma Ltd.

Mankind Pharma

₹ 0.00

0.00 (0.00)%

NSE

BSE

Healthcare

Large-cap - With a market cap of ₹1049.12 Cr.

EX-Date	Purpose
30 05 2023	Quarterly Results & Audited Results
02 08 2023	Quarterly Results
31 10 2023	Quarterly Results
31 01 2024	Quarterly Results
20 09 2024	Raising of Funds Inter alia, to consider and approve the raising of funds by way of issue of non-convertible debentures, commercial papers, other debt securities or any other security or any combination thereof for an amount as may be decided by the Board.
05 11 2024	Quarterly Results
23 01 2025	Quarterly Results
21 05 2025	Audited Results
31 07 2025	Quarterly Results & Interim Dividend

News

01-AUG-2025

Mankind Pharma reports 18% fall in Q1 consolidated net profit

The total consolidated income of the company increased by 23.02% at Rs 3650.23 crore for Q1FY26

12:28 PM

05-JUN-2025

Mankind Pharma gets ESG score of 38.98 from ISS ESG

The company has not verified any data on which this rating has been issued

10:30 AM

09-FEB-2024

Mankind Pharma’s promoters sell 1.62% stake in company

The shares were disposed of at an average price of Rs 2,107.35 apiece, taking the combined deal value to Rs 1,367.57 crore

02:58 PM

11-MAR-2024

Mankind Pharma inks pact with AstraZeneca Pharma India

The agreement is for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate brand Symbicort in India

04:25 PM

15-APR-2025

Mankind Pharma gets nod to incorporate wholly owned subsidiary in Russia

The Board of Directors of the Company at its meeting held on April 14, 2025, has inter-alia, considered and approved the same

10:30 AM

18-DEC-2023

Mankind Pharma makes investment in Actimed Therapeutics

Post this investment the aggregate shareholding of the Company in Actimed will be around 10.19%

10:22 AM

22-MAY-2025

Mankind Pharma reports 11% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 32.47% at Rs 3,330.70 crore for Q4FY25

12:30 PM

22-MAY-2025

Mankind Pharma gets nod to incorporate wholly owned subsidiary in Sri Lanka

The Board of Directors of the Company at its meeting held on May 21, 2025, has approved the same

11:09 AM

24-OCT-2024

Mankind Pharma completes transaction to acquire 100% stake in Bharat Serums and Vaccines

BSV’s established domestic product portfolio offers huge scalability potential through strong registration velocity through niche filings across international markets

09:39 AM

27-DEC-2024

Mankind Pharma, Innovent Biologics partner to commercialise Sintilimab

This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region

11:18 AM